Acquisition-driven momentum: Pennant closed the Signature deal and a larger UnitedHealth/Amedisys asset purchase, and is integrating the latter in a structured “five waves” process expected to conclude by the end of October, with full optimization taking roughly 12–24 months.
Conservative guidance tied to integration risk: Management tempered near-term guidance because of system migrations, rebranding, employee transitions and transitional services agreements, while projecting the acquired book to ramp to an annualized ~10.5% margin in 2026 and longer-term Home Health & Hospice margin goals near 18% (companywide segment EBITDA targets ~16% and Senior Living ~11%).
While the M&A pipeline is “robust,” Pennant plans a more methodical, tuck‑in approach after spending about $200 million on acquisitions last year, and is also investing in local leadership, technology and AI to support organic and inorganic growth.
The Pennant Group (NASDAQ:PNTG) executives struck an optimistic tone about business momentum and growth initiatives during a fireside chat at Oppenheimer’s 36th Annual Healthcare Conference, while also emphasizing a measured approach to integrating major acquisitions and navigating a shifting competitive and regulatory landscape.
Chief Executive Officer Brent Guerisoli said the company finished the year with “a lot of momentum,” describing the prior year as a period focused on growth. He highlighted two major transactions: the completion of the Signature acquisition early in the year, which he said was the company’s largest deal at the time, and a larger acquisition later in the year involving assets related to UnitedHealth Group and Amedisys.
Guerisoli framed the company as “a leadership company,” saying growth creates opportunities for internal leaders, including CEO-in-Training (CIT) participants and other managers across the organization. He added that the company has seen encouraging early signs from its expansion into the Southeast, while acknowledging that significant work remains during the transition and integration period.
Management also pointed to momentum across business lines, including Home Health and Hospice as well as Senior Living, while noting “latent potential” to further optimize operations, create efficiencies, and drive continued growth.
Chief Financial Officer Lynette Walbom said the company’s guidance includes conservatism, largely tied to the scale and complexity of the UnitedHealth Group/Amedisys transaction. She outlined transition factors that could affect results, including system migrations (moving acquired operations from their Homecare Homebase instance to Pennant’s), rebranding efforts, and employee transitions that could affect productivity and revenue.
Walbom also noted that collections early in the transition are being handled under a transitional services agreement (TSA) by UnitedHealth Group and Amedisys, adding another variable the company considered when setting expectations. She said early first-quarter progress suggested the company is “well on our way to having successful transitions and being able to meet guidance.”
Guerisoli added that the company took a similar approach with the Signature acquisition, where the ramp ultimately progressed faster than anticipated. He cautioned that the current integration is “more complex,” larger, and in a geography where Pennant previously had not operated, and said management is intentionally moving methodically to reduce risk and retain strong teams.
Guerisoli said the integration of the newly acquired operations is structured into five waves, split by legacy asset group and service line (home health versus hospice). He said the company was completing the second wave, and expects the full transition process to run through the end of October, with the fifth wave concluding then. By comparison, he said the Signature integration occurred in two waves.
Early feedback has been positive, according to Guerisoli, who emphasized the strength and commitment of local teams and said the company met with “every single team, every single employee” across the portfolio. He cited significant employee tenure and said the acquired staff had been through prior disruption, including earlier changes tied to UnitedHealth Group and the broader uncertainty around Amedisys. He said the teams expressed relief at having clarity and enthusiasm about joining Pennant’s culture-driven organization.
Looking ahead, Guerisoli said the company expects efficiency gains as TSAs roll off and administrative costs decline. He described a 12- to 24-month window to fully optimize the acquired businesses.
On the acquired “book” of business, management discussed a margin ramp. Walbom said that for 2026, the company is looking for an annualized margin “close to 10.5%,” with Guerisoli clarifying that figure reflects a ramping annualized level. Over time, the company’s stated goal is to reach margin levels consistent with the rest of its Home Health and Hospice segment, which Guerisoli described as an 18% target margin prior to noncontrolling interest (NCI). He noted that reaching the higher level would depend on integration execution and timing.
Walbom said companywide guidance assumes margin expansion in both business lines, though core Home Health and Hospice margin improvement is expected to be partially offset by lower margin from the newly acquired Amedisys and LHC assets. She said the company expects an annualized EBITDA margin around 16% for the Home Health and Hospice segment. For Senior Living, she said the company expects margin expansion through the year, leading to an annualized margin around 11%.
Guerisoli said the competitive landscape has changed as large players have been drawn into integration cycles—citing LHC and Amedisys being tied to UnitedHealth Group, CenterWell’s connection to Humana, and disruption at Enhabit. He said Pennant has seen a significant increase in opportunity and described the acquisition environment as “as robust” as it has ever been, though he expects the current lull in competitor activity to be temporary.
He also said the company’s expanded footprint—now including the Southeast and Northeast (through relationships with Hartford)—has increased its national profile and improved payer negotiations. Guerisoli credited expanded scale, investments in a strategic partnerships team, and a focus on quality outcomes, including value-based purchasing performance and rehospitalization rates, as factors that resonate with payers and can support both inorganic and organic growth. He also described opportunities to move from per-visit reimbursement structures to PDGM-like reimbursement with certain managed care partners.
On M&A capacity, Guerisoli said there are “plenty of good deals” available and emphasized three prerequisites for growth: leadership depth, operational strength to support expansion, and attractive transaction opportunities. He said Pennant added over 100 CIT leaders in 2025. However, he said integration work in the Southeast is consuming significant bandwidth, leading the company to be more methodical and focus on tuck-in deals. He also noted the company spent $200 million on acquisitions last year and said it does not expect to grow at that same rate this year given integration priorities.
In Senior Living, Guerisoli said the company has made investments in leadership, building capital improvements, and pricing sophistication. He said occupancy had been relatively flat for a few years, but improved in 2025, which he attributed to balancing occupancy and revenue quality after earlier periods of sharp RevPOR gains in 2023 and 2024. He said RevPOR growth moderated to mid-single digits in 2025, and occupancy increased by two percentage points. Guerisoli said the company is around 81% occupancy and views 85% as an optimization goal, adding that the company expects further occupancy improvement, though acquisitions can temporarily weigh on overall occupancy as new properties are integrated.
On regulation, Guerisoli said the company was “grateful” that the home health rate adjustment was reduced to just over a 1% cut versus the initial proposal, and said CMS acknowledged flaws in its methodology. He said the end of permanent adjustments last year removed a recurring annual headwind, leaving temporary adjustments and the clawback as ongoing factors. While noting uncertainty in CMS decisions, he said the company sees potential relief ahead and suggested the net impact could be closer to neutral over time if temporary adjustments continue to roll on and off.
In closing remarks, Guerisoli reiterated that Pennant’s model centers on local, entrepreneurial leadership and said organic growth is an underappreciated element alongside acquisitions. He also pointed to technology and AI investments as a strategic focus, saying the company believes these initiatives could create meaningful value over the next three to five years.
The Pennant Group (NASDAQ: PNTG) is a publicly traded holding company that provides specialized services to the asset management industry. Through its operating subsidiaries, the company delivers outsourced fund administration, securities lending, prime brokerage, and capital markets solutions designed to support hedge funds, private equity firms, mutual funds and other institutional investors. By leveraging a combination of technology platforms and industry expertise, The Pennant Group helps clients streamline middle- and back-office processes, enhance operational efficiency and manage regulatory requirements.
Key service offerings include fund accounting and reporting, trade settlement and reconciliation, risk monitoring, securities lending programs and execution support across a range of asset classes.
